Home › Research › Risk genes beyond APOE
Alzheimer disease and platelets: how's that relevant
Catricala S, Torti M, Ricevuti G.. Immunity & ageing : I & A, 2012-09-17
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer Disease (AD) is the most common neurodegenerative disorder worldwide, and account for 60% to 70% of all cases of progressive cognitive impairment in elderly patients. At the microscopic level distinctive features of AD are neurons and synapses degeneration, together with extensive amounts of senile plaques and neurofibrillars tangles. The degenerative process probably starts 20-30 years before the clinical onset of the disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Catricala, S., Torti, M., & Ricevuti, G. (2012). Alzheimer disease and platelets: how's that relevant. Immunity & ageing : I & A. https://doi.org/10.1186/1742-4933-9-20
Vancouver
Catricala S, Torti M, Ricevuti G. Alzheimer disease and platelets: how's that relevant. Immunity & ageing : I & A. 2012. doi:10.1186/1742-4933-9-20. PMID: 22985434.
BibTeX
@article{catricala2012-22985434,
author = {Catricala, S. and Torti, M. and Ricevuti, G.},
title = {{Alzheimer disease and platelets: how's that relevant}},
journal = {Immunity \& ageing : I \& A},
year = {2012},
doi = {10.1186/1742-4933-9-20},
pmid = {22985434},
url = {https://doi.org/10.1186/1742-4933-9-20}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- At the microscopic level distinctive features of AD are neurons and synapses degeneration, together with extensive amounts of senile plaques and neurofibrillars tangles.
- The degenerative process probably starts 20-30 years before the clinical onset of the disease.
- Senile plaques are composed of a central core of amyloid β peptide, Aβ, derived from the metabolism of the larger amyloid precursor protein, APP, which is expressed not only in the brain, but even in non neuronal tissues.
- More than 30 years ago, some studies reported that human platelets express APP and all the enzymatic activities necessary to process this protein through the same pathways described in the brain.
Why it matters
This review discusses platelets and their relevance in Alzheimer disease, noting that amyloid precursor protein is expressed in non-neuronal tissues as well as the brain. It is a review of biology and does not report a treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Immunity & ageing : I & A) |
| Journal's citation record | 1 / 4 | Immunity & Ageing: journal h-index 82 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 130 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.1 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 3 / 6 | Cited 4.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Giovanni Ricevuti: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Pavia: institution h-index 809 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22985434) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE
Also in Risk genes beyond APOE
98 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.